+ + + BioBarriers 2020 postponed + + +

The Program Chairs and Organizers of the 
13th International Conference on Biological Barriers 
have decided to postpone the event to 6 – 8 September 2021.

On account of the COVID-19 situation and after consideration 
of various scenarios that may unfold between now and 
the original conference date in August/September 2020, 
we have decided to postpone. 
This decision has been made with a heavy heart 
but seems to be inevitable.

We will now start working on the prearrangement of 
BioBarriers 2021 – and we will keep you all updated on the program.

Our sympathies at this time are with those affected 
all around the world.

Hope you see you at BioBarriers 2021

+ + + + + + + + + + + + + + + + + + + + + + + + + +

The 13th International Conference on Biological Barriers is an international scientific event, organized every two years with constantly 200+ participants from all over the world.

The focus of BioBarriers 2020 is on drug delivery in the context of infection research. Sessions include Delivery of Nucleotides, Barriers and Carriers in Infection, Bacterial Vesicles, Innovative Fabrication Technologies, Microfluidics, Bioprinting and On-the-Chip Technologies. Moreover, we will discuss Novel Polymers and Technologies for Drug Delivery across Biological Barriers.

Target audience are early stage researchers as well as expert scientists and professionals from academia and industry.

The programme combines:

  • international experts presenting their views and latest results
  • opportunities for contributed podium and poster presentations
  • explicit poster session with short oral presentations (poster pitch)
  • industry exhibition – selected companies present their latest technologies

Registration includes free coffee, lunch and dinner for the duration of the conference

Program Committee

Program Chairs and Organizers of BioBarriers 2020

Claus-Michael Lehr is Professor at Saarland University, and also cofounder and head of the department Drug Delivery at the recently established Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). Together with his long lasting colleague Ulrich Schäfer, he developed the BioBarriers conference series and acts as program chair since its beginning in 1997. He received numerous awards and memberships and serves as expert reviewer for research institutions, international corporations and journals. Since 2015, Claus-Michael Lehr is listed yearly by the journal The Medicine Maker as one of the hundred most influential experts of drug development.

Gregor Fuhrmann is a Junior Research Group Leader at the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS). He studied Pharmacy in Berlin and received his doctoral degree in 2013 from the Swiss Federal Institute of Technology ETH Zurich. For his thesis, he received the ETH Medal and the Rottendorf Europapreis award for excellent pharmaceutical research. He then joined the Department of Bioengineering at Imperial College London as a German Academic Exchange Service Postdoc and a Marie-Curie Intra-European Fellow. Since December 2016, he is heading his research group Biogenic Nanotherapeutics (BION) which is dedicated to biomimetic engineering for improved therapy and imaging of infectious diseases.

Brigitta Loretz studied Microbiology at the University of Innsbruck. In April 2007 she received her PhD at the University of Innsbruck, Dep. of Pharmaceutical Technology for her work on novel strategies for oral gene delivery. As postdoc she joined Prof. Lehr’s group at the Saarland University in June 2007. After the foundation of the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), she changed to the new institute and is working there as senior scientist. Her research interests are nano carriers for intracellular delivery of biopharmaceutics, with a special focus on biodegradable polymers.

Partners